Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City

M X Tang, G Maestre, W Y Tsai, X H Liu, L Feng, W Y Chung, M Chun, P Schofield, Y Stern, B Tycko, R Mayeux, M X Tang, G Maestre, W Y Tsai, X H Liu, L Feng, W Y Chung, M Chun, P Schofield, Y Stern, B Tycko, R Mayeux

Abstract

Apolipoprotein-E epsilon 4 (APOE-epsilon 4) has been consistently associated with Alzheimer disease (AD) and may be responsible for an earlier age at onset. We have previously reported a diminished association between APOE-epsilon 4 and AD in African Americans. Using a new method, which allows inclusion of censored information, we compared relative risks by APOE genotypes in an expanded collection of cases and controls from three ethnic groups in a New York community. The relative risk for AD associated with APOE-epsilon 4 homozygosity was increased in all ethnic groups (African American relative risk [RR]=3.0; 95% confidence interval [CI]=1.5-5.9; Caucasian RR=7.3, 95% CI=2.5-21.6; and Hispanic RR=2.5, 95% CI=1.1-5.7), compared with those with APOE-epsilon 3/epsilon 3 genotypes. The risk was also increased for APOE-epsilon 4 heterozygous Caucasians (RR=2.9, 95% CI=1.7-5.1) and Hispanics (RR=1.6, 95% CI=1.1-2.3), but not for African Americans (RR=0.6, 95% Ci=0.4-0.9). The age distribution of the proportion of Caucasians and Hispanics without AD was consistently lower for APOE-epsilon 4 homozygous and APOE-epsilon 4 heterozygous individuals than for those with other APOE genotypes. In African Americans this relationship was observed only in APOE-epsilon 4 homozygotes. These results confirm that APOE genotypes influence the RR of AD in Caucasians and Hispanics. Differences in risk among APOE-epsilon 4 heterozygote African Americans suggest that other genetic or environmental factors may modify the effect of APOE-epsilon 4 in some populations.

References

    1. BMJ. 1994 Sep 10;309(6955):636-8
    1. JAMA. 1994 May 4;271(17):1316-7
    1. JAMA. 1994 Dec 7;272(21):1666-71
    1. Circulation. 1995 Jan 15;91(2):265-9
    1. Hum Genet. 1995 Jan;95(1):46-8
    1. Ann Neurol. 1995 Jan;37(1):118-20
    1. Neurosci Lett. 1994 Aug 15;177(1-2):100-2
    1. Ann Neurol. 1995 Feb;37(2):254-9
    1. JAMA. 1995 May 3;273(17):1354-9
    1. Ann Neurol. 1995 May;37(5):605-10
    1. Lancet. 1994 Jun 18;343(8912):1564-5
    1. J Med Genet. 1994 Mar;31(3):197-200
    1. Arterioscler Thromb. 1994 Jul;14(7):1084-9
    1. Neurosci Lett. 1994 Mar 14;169(1-2):175-8
    1. Hum Hered. 1994 Jul-Aug;44(4):209-13
    1. Arterioscler Thromb. 1994 Sep;14(9):1412-9
    1. Hum Mol Genet. 1994 Apr;3(4):569-74
    1. Ann Neurol. 1995 Jul;38(1):6-14
    1. Ann Neurol. 1995 Sep;38(3):463-5
    1. Neurology. 1984 Jul;34(7):939-44
    1. Arteriosclerosis. 1988 Jan-Feb;8(1):1-21
    1. Dis Markers. 1989 Jan-Mar;7(1):49-55
    1. Genet Epidemiol. 1989;6(2):361-71
    1. JAMA. 1989 Nov 10;262(18):2551-6
    1. J Lipid Res. 1990 Mar;31(3):545-8
    1. Am J Hum Genet. 1991 Jul;49(1):76-87
    1. Am J Hum Genet. 1991 Aug;49(2):338-49
    1. Am J Hum Genet. 1989 Oct;45(4):586-91
    1. Arch Neurol. 1992 May;49(5):453-60
    1. Arch Neurol. 1992 May;49(5):461-7
    1. Am J Hum Genet. 1992 Dec;51(6):1311-24
    1. Am J Cardiol. 1993 Jan 15;71(2):160-5
    1. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81
    1. Metabolism. 1993 Mar;42(3):381-6
    1. Science. 1993 Aug 13;261(5123):921-3
    1. Neurology. 1993 Aug;43(8):1467-72
    1. Lancet. 1993 Sep 4;342(8871):625
    1. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8098-102
    1. Lancet. 1993 Sep 18;342(8873):697-9
    1. Lancet. 1993 Sep 18;342(8873):710-1
    1. Lancet. 1993 Sep 18;342(8873):737
    1. Lancet. 1993 Sep 18;342(8873):738
    1. Ann Neurol. 1993 Nov;34(5):752-4
    1. Nat Genet. 1994 Jan;6(1):29-32
    1. Atherosclerosis. 1994 Jan;105(1):89-95
    1. Nat Genet. 1994 Jun;7(2):180-4

Source: PubMed

3
구독하다